Profile data is unavailable for this security.
About the company
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
- Revenue in USD (TTM)13.59m
- Net income in USD-54.81m
- Incorporated2013
- Employees135.00
- LocationscPharmaceuticals Inc25 Burlington Mall Road, Suite 203BURLINGTON 01803United StatesUSA
- Phone+1 (617) 517-0730
- Fax+1 (302) 655-5049
- Websitehttps://www.scpharmaceuticals.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASP Isotopes Inc | 433.03k | -16.29m | 153.13m | 76.00 | -- | 9.40 | -- | 353.62 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
| Capricor Therapeutics Inc | 25.18m | -22.29m | 155.62m | 101.00 | -- | 6.81 | -- | 6.18 | -0.8708 | -0.8708 | 0.9403 | 0.7256 | 0.4627 | -- | 4.61 | 249,287.80 | -40.96 | -54.12 | -82.59 | -75.13 | -- | -- | -88.52 | -316.25 | -- | -- | 0.13 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Scilex Holding Co | 46.74m | -166.98m | 158.11m | 105.00 | -- | -- | -- | 3.38 | -1.25 | -1.25 | 0.3587 | -1.73 | 0.4977 | 5.61 | 1.67 | 445,171.40 | -121.73 | -- | -- | -- | 66.45 | -- | -244.59 | -- | 0.17 | -11.86 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -37.94m | 162.59m | 42.00 | -- | 12.65 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| ProQR Therapeutics NV | 10.15m | -29.96m | 162.71m | 157.00 | -- | 3.82 | -- | 16.03 | -0.3699 | -0.3699 | 0.1253 | 0.5234 | 0.0616 | -- | 0.332 | 64,636.85 | -17.94 | -35.51 | -21.82 | -40.51 | -- | -- | -291.18 | -926.31 | -- | -- | 0.3229 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Greenwich Lifesciences Inc | 0.00 | -8.89m | 163.43m | 3.00 | -- | 24.33 | -- | -- | -0.6921 | -0.6921 | 0.00 | 0.5215 | 0.00 | -- | -- | 0.00 | -86.87 | -36.43 | -89.30 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Adicet Bio Inc | 0.00 | -142.66m | 164.31m | 143.00 | -- | 0.5085 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Scpharmaceuticals Inc | 13.59m | -54.81m | 164.77m | 135.00 | -- | 4.42 | -- | 12.12 | -1.42 | -1.42 | 0.353 | 1.03 | 0.1243 | 0.7569 | -- | 100,688.90 | -50.13 | -38.23 | -55.33 | -42.31 | 71.96 | -- | -403.22 | -1,360.16 | 6.40 | -18.35 | 0.5105 | -- | -- | -- | -48.79 | -- | -- | -- |
| P3 Health Partners Inc | 1.27bn | -57.77m | 164.96m | 400.00 | -- | 0.4284 | -- | 0.1303 | -0.6494 | -0.6494 | 13.37 | 1.22 | 1.46 | -- | 13.23 | 3,165,938.00 | -21.46 | -- | -96.06 | -- | 2.50 | 0.1781 | -14.72 | -56.93 | -- | -10.33 | 0.1999 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 165.96m | 1.00 | -- | 46.64 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Gossamer Bio Inc | 0.00 | -179.82m | 167.61m | 135.00 | -- | 2.67 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
| Alpha Tau Medical Ltd | 0.00 | -29.16m | 170.00m | 121.00 | -- | 2.01 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 177.93m | 10.00 | -- | 1.95 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 178.36m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
Data as of Apr 22 2024. Currency figures normalised to scPharmaceuticals Inc's reporting currency: US Dollar USD
44.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Dec 2023 | 3.50m | 9.71% |
| AIGH Capital Management LLCas of 31 Dec 2023 | 3.11m | 8.62% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.72m | 4.78% |
| J. Goldman & Co. LPas of 31 Dec 2023 | 1.40m | 3.90% |
| Luther King Capital Management Corp.as of 31 Dec 2023 | 1.39m | 3.87% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.32m | 3.65% |
| Thrivent Asset Management LLCas of 31 Dec 2023 | 1.05m | 2.91% |
| Walleye Capital LLCas of 31 Dec 2023 | 871.49k | 2.42% |
| Worth Venture Partners LLCas of 31 Dec 2023 | 771.34k | 2.14% |
| Tejara Capital Ltd.as of 31 Dec 2023 | 757.77k | 2.10% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
